Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

DO, MPH

Do you check baseline or intermittent labs on dupilumab or tralokinumab for AD?

JAK Inhibitors

You. When we're using the new systemic agents that are available for treating moderate to severe atopic dermatitis like dupilumab and more recently, trollkinumab, it's really not a need to check laboratory studies at baseline. These therapies work more along that th two cytokine pathway and even really more along what we would call almost an allergy type pathway, and they're not really considered immunosuppressive therapies. One comment I would make is that in the future, as we continue to elucidate different comorbidities associated with atopper dermatitis, for instance cardiovascular disease, our thoughts may change on that. And so I don't think at this point, all of us would agree that laboratory testing is not required for the injectable agents of dupliumab and trilogyumab.